Follow Us: social media social media social media        

Dilatrend® (carvedilol): Warning on Severe Adverse Cutaneous Reactions

Date: 21 May 2014

Description: Healthcare professionals should take note that very rare cases of severe adverse cutaneous reactions such as toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) have been reported during treatment with carvedilol. The drug should be permanently discontinued in patients who experience such reactions possibly attributable to carvedilol. For further details, please refer to the Direct Healthcare Professional Communication (DHPC) issued by Roche (Malaysia) Sdn. Bhd. in agreement with NPCB.

qrcode